APP C-Terminal Fragment: Effect on Cognition and Aβ

About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
July 01, 2017 - September 30, 2020
Grant ID
A2017443S
Goals
For the past two decades, researchers in Alzheimer’s disease (AD) field have focused on the neurotoxicity associated with Aβ peptide production and accumulation. Amyloid beta (Aβ) is a small peptide molecule generated from cleavage of amyloid precursor protein (APP). Our proposed studies will explore the APP molecule as a whole cellular component that could affect brain function and memory processing. We will focus more specifically on the intracellular fragment of APP that could initiate signaling events. We aim to deliver a small peptide fragment to the brain of familial AD mouse models using a viral strategy. The overall goal is to develop novel rational therapeutics aimed at preserving cognitive function and reducing Aβ burden in those suffering from AD.
Summary
Our research will test the hypothesis that production of an intracellular fragment originating from APP could rescue memory decline in AD mice. Viral injection in the brain will facilitate the overproduction of this fragment. We will consider the likelihood that viral transduction of this short peptide could attenuate Aβ production and deposition in AD mice, and rescue their memory function. We will characterize the mechanisms underlying these changes.
Grantee institution at the time of this grant: University of Chicago
Related Grants
Alzheimer's Disease Research
Neurostimulation to Improve Depression and Memory in Dementia
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Davide Cappon, PhD
Current Organization
Hebrew Rehabilitation Center
Neurostimulation to Improve Depression and Memory in Dementia
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Davide Cappon, PhD
Current Organization
Hebrew Rehabilitation Center
Alzheimer's Disease Research
Unfolding Alzheimer's Tau Therapies: Near- and Long-Term Approaches
Active Dates
July 01, 2023 - June 30, 2026
Principal Investigator
Paul Seidler, PhD
Current Organization
University of Southern California
Unfolding Alzheimer's Tau Therapies: Near- and Long-Term Approaches
Active Dates
July 01, 2023 - June 30, 2026

Principal Investigator
Paul Seidler, PhD
Current Organization
University of Southern California
Alzheimer's Disease Research
A Novel Test for Alzheimer’s Disease Based on DNA Circulating in Blood
Active Dates
July 01, 2022 - June 30, 2025
Principal Investigator
Yuval Dor, PhD
Current Organization
Hebrew University of Jerusalem
A Novel Test for Alzheimer’s Disease Based on DNA Circulating in Blood
Active Dates
July 01, 2022 - June 30, 2025

Principal Investigator
Yuval Dor, PhD
Current Organization
Hebrew University of Jerusalem